Related Experiment Video

Updated: May 16, 2026

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity
07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

Organometallic anticancer agents that interfere with cellular energy processes: a subtle approach to inducing cancer

Alexey A Nazarov1, Daniel Gardini, Mathurin Baquié

  • 1Institute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology, 1015 Lausanne, Switzerland.

Dalton Transactions (Cambridge, England : 2003)
|December 11, 2012
PubMed

Insights

New hybrid compounds combine ruthenium-arene fragments with indazole derivatives to inhibit cancer cell glycolysis. These novel agents show synergistic effects, particularly in human glioblastoma cells, offering a promising antimetastatic strategy.

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Metabolic Pathways

Background:

  • Aerobic glycolysis (the Warburg effect) is a hallmark of cancer metabolism.
  • Targeting cancer-specific metabolic pathways presents a viable therapeutic strategy.
  • Developing novel antimetastatic agents is crucial for improving cancer treatment outcomes.

Purpose of the Study:

  • To synthesize and evaluate novel hybrid compounds with potential antimetastatic activity.
  • To investigate the inhibitory effects of these compounds on aerobic glycolysis in cancer cells.
  • To explore the synergistic action between ruthenium-arene fragments and indazole derivatives.

Main Methods:

  • Synthesis of hybrid compounds linking ruthenium-arene and indazole-3-carboxylic acid moieties.
  • In vitro evaluation of compound efficacy across diverse cancer cell lines.
  • Assessment of inhibition of aerobic glycolysis.
  • Analysis of synergistic effects between compound components.

Main Results:

  • Successful preparation of two hybrid compounds.
  • Demonstrated inhibition of aerobic glycolysis in various cancer cell lines.
  • Significant activity observed in human glioblastoma cells.
  • Apparent synergistic action between the ruthenium-arene and indazole components.

Conclusions:

  • The novel hybrid compounds effectively inhibit cancer cell aerobic glycolysis.
  • Synergistic effects enhance the antimetastatic potential of these agents.
  • These compounds represent a promising new class of anticancer drugs, especially for glioblastoma.

More Related Videos

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...